WHY INDIA
← BACK

Why India.

The structural case for India manufacturing. A generational opportunity driven by global supply chain shifts and domestic policy tailwinds.

Manufacturing GDP
$400B+
Growing 8-10% annually
Target by 2030
$1T
Government policy goal
PLI Investment
$30B+
Committed incentives
Workforce
500M+
Working age population
STRUCTURAL TAILWINDS

The forces driving growth.

01

CHINA+1 DIVERSIFICATION

Global supply chains de-risking from China concentration. India positioned as primary beneficiary for manufacturing relocation.

40% of MNCs actively diversifying
02

PLI SCHEMES

Production Linked Incentive schemes across 14 sectors providing 4-6% incentives on incremental production.

$30B+ committed incentives
03

DEMOGRAPHIC DIVIDEND

Youngest major economy. 500M+ working age population. Labor cost advantage vs developed markets.

Median age: 28 years
04

INFRASTRUCTURE BUILDOUT

Massive investment in logistics, ports, and industrial corridors. Gati Shakti national master plan.

$1.3T infrastructure pipeline
SECTOR OPPORTUNITIES

Where we see value.

Specialty Chemicals
MARKET SIZE
$35B
CAGR
12%
THESIS
Import substitution, China+1
Packaging Materials
MARKET SIZE
$70B
CAGR
15%
THESIS
Consumption, sustainability
Pharmaceuticals
MARKET SIZE
$50B
CAGR
10%
THESIS
API manufacturing, generics
KEY INSIGHT

Challenges are opportunities.

Every challenge in India manufacturing is an opportunity for operators with the right playbook.

Fragmentation

Thousands of sub-scale players. Consolidation opportunity.

Talent Gap

Skilled workforce shortage. Training infrastructure needed.

Capital Access

Family businesses underbanked. Growth capital scarce.

Technology Lag

Limited ERP/automation adoption. Greenfield for modernization.

INVESTMENT THESIS

A generational opportunity.

India's manufacturing sector is at an inflection point. Global supply chain diversification, government incentives, and demographic tailwinds create a generational opportunity. The fragmented landscape—thousands of family-owned manufacturers operating at sub-scale—is the opportunity. With operational expertise and patient capital, we can build scaled, competitive platforms.